Health-related Quality of Life (HRQoL) in Patients with advanced cutaneous Squamous Cell Carcinoma (CSCC) treated with Cemiplimab: Post hoc exploratory Analysis of a clinical Phase-2-Study

被引：0
|
作者：
Migden, M. R. [1 ,2 ]
Rischin, D. [3 ]
Sasane, M. [4 ]
Mastey, V. [5 ]
Pavlick, A. [6 ]
Schmults, C. D. [7 ]
Chen, Z. [5 ,8 ]
Guminski, A. [9 ]
Hauschild, A. [10 ]
Bury, D. [11 ]
Chang, A. L. S. [12 ]
Rabinowits, G. [13 ]
Ibrahim, S. [8 ]
Lowy, I. [5 ]
Fury, M. G. [5 ]
Li, S. [5 ]
Chen, C. I. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Sanofi, Bridgewater, MA USA
[5] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[6] NYU, Langone Med Ctr, Dept Med Oncol, New York, NY USA
[7] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA
[8] Rochester Med Ctr, Dept Dermatol, Rochester, NY USA
[9] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia
[10] Univ Hosp UKSH, Dept Dermatol, Kiel, Germany
[11] Sanofi, Cambridge, MA USA
[12] Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA
[13] Baptist Hlth South Florida, Miami Canc Inst, Dept Hematol Oncol, Miami, FL USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV32
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [1] Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.
    Migden, Michael Robert
    Rischin, Danny
    Sasane, Medha
    Mastey, Vera
    Pavlick, Anna
    Schmults, Chrysalyne D.
    Chen, Zhen
    Guminski, Alexander David
    Hauschild, Axel
    Bury, Denise
    Chang, Anne Lynn S.
    Rabinowits, Guilherme
    Ibrahim, Sherrif F.
    Lowy, Israel
    Fury, Matthew G.
    Li, Siyu
    Chen, Chieh-I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial
    Peris, Ketty
    Inocencio, Timothy J.
    Stratigos, Alexander J.
    Lewis, Karl D.
    Eroglu, Zeynep
    Chang, Anne Lynn S.
    Ivanescu, Cristina
    Sekulic, Aleksandar
    Fury, Matthew G.
    Chen, Chieh-, I
    Quek, Ruben G. W.
    CANCER MEDICINE, 2024, 13 (14):
  • [3] Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial
    Stratigos, Alexander J.
    Chen, Chieh-I
    Ivanescu, Cristina
    Lewis, Karl D.
    Peris, Ketty
    Bechter, Oliver
    Harnett, James
    Mastey, Vera
    Reaney, Matthew
    Daskalopoulou, Christina
    LaFontaine, Patrick R.
    Konidaris, Gerasimos
    Bury, Denise
    Yoo, Suk-Young
    Mohan, Kosalai
    Coates, Ebony
    Bowler, Timothy
    Fury, Matthew G.
    Sekulic, Aleksandar
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 167 - 167
  • [4] Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months
    Rischin, Danny
    Khushalani, Nikhil I.
    Schmults, Chrysalyne D.
    Guminski, Alexander
    Chang, Anne Lynn S.
    Lewis, Karl D.
    Lim, Annette M.
    Hernandez-Aya, Leonel
    Hughes, Brett G. M.
    Schadendorf, Dirk
    Hauschild, Axel
    Stankevich, Elizabeth
    Booth, Jocelyn
    Yoo, Suk-Young
    Okoye, Emmanuel
    Lowy, Israel
    Fury, Matthew G.
    Migden, Michael R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 166 - 166
  • [5] Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.
    Stratigos, Alexander J.
    Chen, Chieh-I
    Ivanescu, Cristina
    Lewis, Karl D.
    Peris, Ketty
    Bechter, Oliver Edgar
    Harnett, James
    Mastey, Vera
    Reaney, Matthew
    Daskalopoulou, Christina
    LaFontaine, Patrick R.
    Konidaris, Gerasimos
    Bury, Denise
    Yoo, Suk Young
    Mohan, Kosalai Kal
    Coates, Ebony
    Bowler, Timothy Geoffrey
    Fury, Matthew G.
    Sekulic, Aleksandar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] First interims analysis of a two cohort registry study for patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab or other approaches
    Gutzmer, R.
    Geusau, A.
    Heppt, M.
    Leiter-Stoeppke, U.
    GunTinas-Lichius, O.
    Duecker, P.
    Utikal, J. S.
    Loquai, C.
    Grabbe, S.
    Terheyden, P.
    Ziller, F.
    Tschechne, B.
    Gschnell, M.
    Mohr, P.
    Heinzerling, L.
    Grimmelmann, I.
    Dippel, E.
    Hassel, J. C.
    Kaatz, M.
    Simon, J.
    Zahn, M. O.
    Ulrich, J.
    Gambichler, T.
    Welzel, J.
    Ramelyte, E.
    Weichenthal, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 44 - 44
  • [7] Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
    Migden, M. R.
    Schmults, C.
    Khushanlani, N.
    Guminski, A.
    Chang, A. L.
    Lewis, K.
    Ansstas, G.
    Bowyer, S. E.
    Hughes, B. G. M.
    Schadendorf, D.
    Modi, B.
    Dunn, L.
    Flatz, L.
    Hauschild, A.
    Yoo, S-Y.
    Booth, J.
    Seebach, F.
    Lowy, I.
    Fury, M. G.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S918 - S919
  • [8] Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.
    Rischin, Danny
    Khushalani, Nikhil I.
    Schmults, Chrysalyne D.
    Guminski, Alexander David
    Chang, Anne Lynn S.
    Lewis, Karl D.
    Lim, Annette May Ling
    Hernandez-Aya, Leonel Fernando
    Hughes, Brett Gordon Maxwell
    Schadendorf, Dirk
    Hauschild, Axel
    Stankevich, Elizabeth
    Booth, Jocelyn
    Li, Siyu
    Chen, Zhen
    Okoye, Emmanuel
    Lowy, Israel
    Fury, Matthew G.
    Migden, Michael Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results
    Rischin, D.
    Hughes, B. G. M.
    Basset-Seguin, N.
    Schadendorf, D.
    Bowyer, S.
    Trabelsi, S.
    Meier, F.
    Eigentler, T.
    Echarren, V. Casado
    Migden, M. R.
    Hauschild, A.
    Schmults, C. D.
    Yoo, S-Y.
    Paccaly, A.
    Jankovic, V.
    Seebach, F.
    Drutman, S.
    Booth, J.
    Fury, M. G.
    Guminski, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S886 - S887
  • [10] KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).
    Bratland, Ase
    Munoz-Couselo, Eva
    Mortier, Laurent
    Roshdy, Osama
    Gonzalez, Rene
    Schachter, Jacob
    Arance, Ana Maria
    Grange, Florent
    Meyer, Nicolas
    Joshi, Abhishek Jagdish
    Billan, Salem
    Hughes, Brett Gordon Maxwell
    Grob, Jean-Jacques
    Ramakrishnan, Karthik
    Zhang, Eric
    Gumuscu, Burak
    Swaby, Ramona F.
    Gutzmer, Ralf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345